Respiratory functional evaluation and pulmonary hyperinflation in asymptomatic smokers: Preliminary study
Read
8604
Timeswas read the article
2648
Total PDF
5956
Total HTML
Share statistics
array:20 [ "pii" => "X0873215915188393" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2014.07.007" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:126-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3713 "formatos" => array:3 [ "EPUB" => 249 "HTML" => 2483 "PDF" => 981 ] ] "itemSiguiente" => array:16 [ "pii" => "X0873215915188408" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2014.08.005" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:132-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4210 "formatos" => array:3 [ "EPUB" => 250 "HTML" => 2834 "PDF" => 1126 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Clinical impact of adaptive servoventilation compared to other ventilatory modes in patients with treatment-emergent sleep apnea, central sleep apnea and Cheyne–Stokes respiration" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "132" "paginaFinal" => "137" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "Efficacy of adaptive servoventilation (ASV) on sleepiness." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Sílvia Correia, Vitória Martins, Liliana Sousa, Joaquim Moita, Fátima Teixeira, José Moutinho dos Santos" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Sílvia" "apellidos" => "Correia" ] 1 => array:2 [ "nombre" => "Vitória" "apellidos" => "Martins" ] 2 => array:2 [ "nombre" => "Liliana" "apellidos" => "Sousa" ] 3 => array:2 [ "nombre" => "Joaquim" "apellidos" => "Moita" ] 4 => array:2 [ "nombre" => "Fátima" "apellidos" => "Teixeira" ] 5 => array:2 [ "nombre" => "José Moutinho" "apellidos" => "dos Santos" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188408?idApp=UINPBA00004E" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188408/v0_201604141146/en/main.assets" ] "itemAnterior" => array:16 [ "pii" => "X0873215915188385" "issn" => "08732159" "doi" => "10.1016/j.rppnen.2014.09.009" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Rev Port Pneumol. 2015;21:113-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5455 "formatos" => array:3 [ "EPUB" => 224 "HTML" => 4239 "PDF" => 992 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "113" "paginaFinal" => "125" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "descripcion" => array:1 [ "en" => "Case 21: 2+ CK20 expression; acinar pattern. 200×." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vitor Sousa, Carolina Rodrigues, Maria Silva, Ana Maria Alarcão, Lina Carvalho" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Vitor" "apellidos" => "Sousa" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Rodrigues" ] 2 => array:2 [ "nombre" => "Maria" "apellidos" => "Silva" ] 3 => array:2 [ "nombre" => "Ana Maria" "apellidos" => "Alarcão" ] 4 => array:2 [ "nombre" => "Lina" "apellidos" => "Carvalho" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188385?idApp=UINPBA00004E" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188385/v0_201604141146/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Respiratory functional evaluation and pulmonary hyperinflation in asymptomatic smokers: Preliminary study" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "126" "paginaFinal" => "131" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Gomes, F. Luís, A. Tavares, N. Sousa, S. Correia, M. Reis" "autores" => array:6 [ 0 => array:4 [ "Iniciales" => "R." "apellidos" => "Gomes" "email" => array:1 [ 0 => "ritad_gomes@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 1 => array:3 [ "Iniciales" => "F." "apellidos" => "Luís" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "Iniciales" => "A." "apellidos" => "Tavares" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 3 => array:3 [ "Iniciales" => "N." "apellidos" => "Sousa" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 4 => array:3 [ "Iniciales" => "S." "apellidos" => "Correia" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 5 => array:3 [ "Iniciales" => "M." "apellidos" => "Reis" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Pulmonology Service, Sousa Martins Hospital, Local Health Unit, Guarda, Portugal" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Faculty of Health Sciences of the University of Beira Interior, Covilhã, Portugal" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "<span class="elsevierStyleSup">*</span>" "correspondencia" => "Corresponding author. ritad_gomes@hotmail.com" ] ] ] ] "textoCompleto" => "<a name="sec0005" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Introduction</span><p class="elsevierStylePara">Smoking has devastating health effects and is a recognized risk factor for the development of cardiovascular, cerebrovascular, respiratory, and oncological diseases.<a href="#bib8" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">1</span></a> The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the diagnosis of chronic obstructive pulmonary disease (COPD) based on a reduction in the FEV1/FVC ratio.<a href="#bib9" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">2</span></a> However, this diagnostic criterion is valid only for advanced COPD, leading to the underdiagnosis of early functional changes in chronic smoking.<a href="#bib10" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a> There are few studies concerning pulmonary function alterations in smokers and the deleterious effects of smoking on functional parameters vary, depending on the studies.</p><p class="elsevierStylePara">Cigarette smoking has a detrimental effect on the airways, causing inflammation and, consequently, airflow limitations and lung hyperinflation.<a href="#bib11" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">, </span><a href="#bib12" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">5</span></a> In thoracic radiographs, one sign of lung hyperinflation is the reduction in the cardiothoracic index (‘heart in gout’). Some authors claim that a reduction in FEV1 is more than just a measure of airflow limitation, that it is, in fact, a marker of premature death, with a wideranging utility in assessing the risks of COPD, lung cancer, coronary artery disease, and stroke, which collectively account for 70–80% of premature deaths in smokers.<a href="#bib13" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">6</span></a> Some studies have encouraged the use of new methods in the detection of precursory anomalies of pulmonary disease during the subclinical phase in patients at risk.</p><p class="elsevierStylePara">The authors present a case control study developed in outpatient clinic with the smoking cessation program at Sousa Martins Hospital (HSM), Local Health Unit, Guarda (Portugal). The main objective of our study was to investigate the respiratory function and lung hyperinflation in asymptomatic smokers without a history of lung pathology and with normal chest radiographs. Secondary objectives consisted of identifying tobacco-related diseases and correlating tobacco consumption, duration of exposure to tobacco smoke, and urinary cotinine with the existence of tobacco-related disease.</p><a name="sec0010" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Materials and methods</span><p class="elsevierStylePara">The authors developed a case-controlled study paired by sex, age and body mass index. The cases were defined as smokers (with a smoking habit for at least one year), who presented for their first appointment at the smoking cessation program at HSM during the period of 11 December 2012 to 8 December 2013, without respiratory symptoms and with normal chest radiographs. Smoking subgroups were integrated using evidence of the history of tobacco-related pathology. The exclusion criterion was applied to cases previously diagnosed with pulmonary pathology.</p><p class="elsevierStylePara">The controls were participants who exhibited normal examination in plethysmography and chest radiographs in HSM. The following exclusion criteria were applied to the controls: known prior history of pulmonary pathology and current and/or past smoking. In the controls, maximum passive exposure was assumed for the determination of carbon monoxide (CO) in the exhaled air (0–6 ppm) and urinary cotinine (<150 ng/mL).</p><p class="elsevierStylePara">The pulmonary function tests were performed using the Plethysmograph Autobox DI SensorMedics 6200 (California, USA) at the Department of Pathophysiology of Respiratory Diseases at HSM. The technical recommendations and standardized reference values of the American Thoracic Society were used to perform the functional tests. A chest X-ray was obtained while the patient was in the standing and forward positions at maximal inspiration, which complies with the criteria for good technical quality. The ratio between the maximum transverse diameter of the heart and the maximum internal diameter of the chest (the calculation of the cardiothoracic index) was determined. A normal thoracic radiograph was considered to be one without pleuroparenchymal alterations and with a cardiothoracic index below 0.5.</p><p class="elsevierStylePara">As a biomarker of current smoking, a determination of the CO in the exhaled air was used. Cotinine in the urine was used as a marker for the cumulative consumption of tobacco intake. The measurement of the CO in the exhaled air was performed during the consultation period of smoking cessation in the Micro Medical smoke check (Kent, England). Assays were stratified into the following CO levels: 0–6 ppm, green = no smoking; 7–10 ppm, yellow = light smoker; 11–20 ppm, red = strong smoker; and >20 ppm, red with beep = very strong smoker. The assay of urinary cotinine was executed using gas/mass spectrophotometry chromatography. The assays of urinary cotinine were stratified as follows: <150 ng/mL = passive smoking; 150–499 ng/mL = light smoker; 500–2500 ng/mL = moderate smoker; and >2500 ng/mL = strong smoker.</p><p class="elsevierStylePara">The criteria for hyperinflation included the presence of either a reduction in the cardiothoracic index or an increase in RV/TLC measured using plethysmography. The minimum value of the cardiothoracic index that defines hyperinflation is not yet clearly established in the literature.</p><p class="elsevierStylePara">Statistical analyses were performed using IBM SPSS Statistics software 19<span class="elsevierStyleSup">®</span>. Exploratory and descriptive analyses were applied to the variables, and in the continuous variables, such as the <span class="elsevierStyleItalic">T</span>-test (2 groups) and the Pearson correlation coefficient. The level of significance was set at <span class="elsevierStyleItalic">p</span> < 0.05.</p><a name="sec0015" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Results</span><p class="elsevierStylePara">During the study period, 64 subject samples were obtained: 32 cases and 32 controls. The 32 cases included smokers in the smoking cessation program at HSM: 65.6% were male, and 34.4% were female. The mean age of male subjects was 45.57 years, and that of female subjects was 37.27 years. There were statistically significant differences between the groups (<span class="elsevierStyleItalic">p</span> < 0.05). The controls included 32 non-smoking individuals, matched with cases by sex, age, and body mass index. The lung function tests were performed at the Division of Respiratory Pathophysiology, HSM. <a href="#t0005" class="elsevierStyleCrossRefs">Table 1</a>, <a href="#t0010" class="elsevierStyleCrossRefs">Table 2</a> characterize the cases by gender in terms of age at onset of smoking, tobacco consumption, urinary cotinine assay, and CO in exhaled air.</p><p class="elsevierStylePara">Table 1. Characteristics of smokers by gender.</p><a name="t0005" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td>Variables</td><td colspan="4">Smokers (<span class="elsevierStyleItalic">n</span> = 32)</td></tr><tr align="left"><td> </td><td>Male subjects<br></br>(<span class="elsevierStyleItalic">n</span> = 21)<br></br>Mean ± standard deviation</td><td>Female subjects<br></br>(<span class="elsevierStyleItalic">n</span> = 11)<br></br>Mean ± standard deviation</td><td>Total<br></br>(<span class="elsevierStyleItalic">n</span> = 32)<br></br>Mean ± standard deviation</td><td><span class="elsevierStyleItalic">T</span> test<br></br>(<span class="elsevierStyleItalic">p</span> value)</td></tr><tr align="left"><td>Body mass index (kg/m<span class="elsevierStyleSup">2</span>)</td><td>26.45 ± 4.17</td><td>25.06 ± 5.02</td><td>25.97 ± 4.45</td><td>0.41</td></tr><tr align="left"><td>Age (years)</td><td>45.57 ± 11.63</td><td>37.27 ± 6.74</td><td>42.72 ± 10.86</td><td>0.038</td></tr><tr align="left"><td>Age of smoking initiation (years)</td><td>16.67 ± 4.73</td><td>16.83 ± 3.66</td><td>16.72 ± 4.33</td><td>0.927</td></tr><tr align="left"><td>Tobacco consumption (packs per year)</td><td>30.33 ± 14.46</td><td>12.73 ± 5.26</td><td>24.28 ± 14.69</td><td>2.91 × 10<span class="elsevierStyleSup">−5</span></td></tr><tr align="left"><td>Urinary cotinine (ng/mL)</td><td>1315.33 ± 895.45</td><td>699.91 ± 465.00</td><td>1103.78 ± 821.74</td><td>0.042</td></tr></table><p class="elsevierStylePara">Table 2. Determination of CO in exhaled air in smokers by gender.</p><a name="t0010" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td>Determination of CO in exhaled air (ppm)</td><td colspan="3">Smokers (<span class="elsevierStyleItalic">n</span> = 32)</td></tr><tr align="left"><td> </td><td>Male subjects<br></br>(<span class="elsevierStyleItalic">n</span> = 21)<br></br><span class="elsevierStyleItalic">n</span> (%)</td><td>Female subjects<br></br>(<span class="elsevierStyleItalic">n</span> = 11)<br></br><span class="elsevierStyleItalic">n</span> (%)</td><td>Total<br></br>(<span class="elsevierStyleItalic">n</span> = 32)<br></br><span class="elsevierStyleItalic">n</span> (%)</td></tr><tr align="left"><td>0–6 = ‘non-smoker’</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr align="left"><td>7–10 = ‘light smoker’</td><td>0 (0%)</td><td>1 (9.09%)</td><td>1 (3.13%)</td></tr><tr align="left"><td>11–20 = ‘strong smoker’</td><td>10 (47.62%)</td><td>8 (72.73%)</td><td>18 (56.25%</td></tr><tr align="left"><td>>20 = ‘very strong smoker’</td><td>11 (52.38%)</td><td>2 (18.18%)</td><td>13 (40.63%)</td></tr></table><p class="elsevierStylePara">It was found that the age of onset of smoking was similar in both genders. Female smokers had a mean tobacco consumption (12.73 packs per year) and mean cotinine (699.91 ng/mL), which was lower than that of the male subjects (30.33 packs per year and 1315.33 ng/mL), with statistical significance (<span class="elsevierStyleItalic">p</span> < 0.05). With regard to CO in exhaled air, 84.62% of the male subjects were considered to be strong smokers vs. 15.38% of the female subjects. The mean duration of exposure to smoking in male subjects was 28.9 years and 20.45 years for female subjects, with statistically significant differences (<span class="elsevierStyleItalic">p</span> < 0.05).</p><p class="elsevierStylePara">There was a weak correlation between urinary cotinine and tobacco consumption (<span class="elsevierStyleItalic">r</span> = 0.124, <span class="elsevierStyleItalic">p</span> = 0.5).</p><p class="elsevierStylePara">A review of the cases and controls using plethysmography is shown in <a href="#t0015" class="elsevierStyleCrossRefs">Table 3</a>. In the cases identified, 9.38% (<span class="elsevierStyleItalic">n</span> = 3) of the smokers exhibited spirometric COPD criteria: mean FEV1/FVC 65% and mean FEV1 89%. The mean FEV1/FVC of the cases was 77.78% (standard deviation [SD] = 6.50%), with 81.41% in the controls (SD = 5.84%), <span class="elsevierStyleItalic">p</span> < 0.05. The means of the FEF 75% and FEF 25–75% were also lower. The mean FEF 75% was 63.78% (SD = 26.44%) in the cases and 86.09% in the controls (SD = 28.99%), <span class="elsevierStyleItalic">p</span> < 0.05. The mean FEF 25–75% in the cases was 83.16% (SD = 26.44%) and 97.19% (SD = 23.82) in the controls (<span class="elsevierStyleItalic">p</span> < 0.05). The reduction was greater in the FEF 75% and FEF 25–75% parameters.</p><p class="elsevierStylePara">Table 3. Evaluation by plethysmography of smokers and controls.</p><a name="t0015" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td>Respiratory function tests</td><td>Smokers<br></br>(<span class="elsevierStyleItalic">n</span> = 32)<br></br>Mean ± standard deviation</td><td>Controls<br></br>(<span class="elsevierStyleItalic">n</span> = 32)<br></br>Mean ± standard deviation</td><td><span class="elsevierStyleItalic">T</span> test<br></br>(<span class="elsevierStyleItalic">p</span> value)</td></tr><tr align="left"><td>FVC (%)</td><td>110.34 ± 13.49</td><td>108.84 ± 14.87</td><td>0.674</td></tr><tr align="left"><td>FEV1 (%)</td><td>102.78 ± 12.06</td><td>106.13 ± 12.96</td><td>0.289</td></tr><tr align="left"><td>FEV1/FVC (%)</td><td>77.88 ± 6.50</td><td>81.41 ± 5.84</td><td>0.026</td></tr><tr align="left"><td>FEF 25% (%)</td><td>92.78 ± 21.47</td><td>88.91 ± 17.44</td><td>0.431</td></tr><tr align="left"><td>FEF 50% (%)</td><td>94.75 ± 31.86</td><td>105.34 ± 26.61</td><td>0.154</td></tr><tr align="left"><td>FEF 75% (%)</td><td>63.78 ± 26.44</td><td>86.09 ± 28.99</td><td>0.002</td></tr><tr align="left"><td>FEF 25–75% (%)</td><td>83.16 ± 26.44</td><td>97.19 ± 23.82</td><td>0.029</td></tr><tr align="left"><td>PEF (%)</td><td>91.41 ± 17.61</td><td>87.59 ± 16.79</td><td>0.379</td></tr><tr align="left"><td>TLC (%)</td><td>104.09 ± 13.42</td><td>100.16 ± 12.79</td><td>0.234</td></tr><tr align="left"><td>RV (%)</td><td>94.5 ± 27.11</td><td>88.97 ± 19.88</td><td>0.356</td></tr><tr align="left"><td>RV/TLC (%)</td><td>27.53 ± 7.63</td><td>27.81 ± 6.00</td><td>0.870</td></tr><tr align="left"><td>Airway resistance – raw (L/s/cmH<span class="elsevierStyleInf">2</span>O)</td><td>0.2440 ± 0.091</td><td>0.2615 ± 0.120</td><td>0.513</td></tr><tr align="left"><td rowspan="2">Specific airway conductance – sGaw (cmH<span class="elsevierStyleInf">2</span>O/L/s)</td><td>♂ 1.122 ± 0.564</td><td>♂ 1.1057 ± 0.477</td><td>♂ 0.920</td></tr><tr align="left"><td>♀ 1.300 ± 0.4306</td><td>♀ 1.543 ± 0.640</td><td>♀ 0.309</td></tr></table><p class="elsevierStylePara">The reductions in FEV1/FVC, FEF 75% and FEF 25–75% were correlated inversely with tobacco consumption, but this was not statistically significant (<span class="elsevierStyleItalic">r</span> = −0.305 and <span class="elsevierStyleItalic">p</span> = 0.089, <span class="elsevierStyleItalic">r</span> = −0.203 and <span class="elsevierStyleItalic">p</span> = 0.265, <span class="elsevierStyleItalic">r</span> = −0.15 and <span class="elsevierStyleItalic">p</span> = 0.391, respectively).</p><p class="elsevierStylePara">Regarding the assessment of the cardiothoracic index, the mean was 0.424 (SD = 0.04) in the cases and 0.458 (SD = 0.04) in the controls, with a statistically significant difference (<span class="elsevierStyleItalic">p</span> < 0.05). A moderate correlation between the cardiothoracic index and TLC was found in the cases (<span class="elsevierStyleItalic">r</span> = −0.371, <span class="elsevierStyleItalic">p</span> < 0.05).</p><p class="elsevierStylePara">Approximately 31.2% (10) of the cases had a history of extra-pulmonary pathology associated with tobacco: 21.88% (seven patients) had hypertension, 6.25% (two cases) had stroke, 3.13% (one case) had acute myocardial infarction and 3.13% (one case) had repeated miscarriages. 9.38% (three smokers) were diagnosed with COPD. In 68.8% (22 smokers), there was no history of tobacco-related disease. <a href="#t0020" class="elsevierStyleCrossRefs">Table 4</a> shows the comparison of the cases in subgroups, with and without tobacco-related disease, in relation to age, age at smoking onset, tobacco consumption, duration of tobacco exposure, urinary cotinine assay, plethysmography variables, and cardiothoracic index. In relation to the distribution by gender in these two subgroups, it was verified that among the smokers with tobacco-related pathology (<span class="elsevierStyleItalic">n</span> = 12), eight were male and six were female; among smokers without tobacco-related pathology (<span class="elsevierStyleItalic">n</span> = 20), 13 were male and seven were female.</p><p class="elsevierStylePara">Table 4. Analysis of subgroups of smokers with and without tobacco-related pathology.</p><a name="t0020" class="elsevierStyleCrossRefs"></a><p class="elsevierStylePara"></p><table><tr align="left"><td>Variables</td><td>Smokers with tobacco-related pathology and COPD<br></br>(<span class="elsevierStyleItalic">n</span> = 12)<br></br>Mean ± standard deviation</td><td>Smokers without tobacco-related pathology<br></br>(<span class="elsevierStyleItalic">n</span> = 20)<br></br>Mean ± standard deviation</td><td><span class="elsevierStyleItalic">T</span> test<br></br>(<span class="elsevierStyleItalic">p</span> value)</td></tr><tr align="left"><td>Age (years)</td><td>48.33 ± 10.13</td><td>39.35 ± 10.05</td><td>0.021</td></tr><tr align="left"><td>Age of smoking initiation (years)</td><td>17.25 ± 4.07</td><td>16.40 ± 4.55</td><td>0.599</td></tr><tr align="left"><td>Tobacco consumption (packs per year)</td><td>27.75 ± 14.22</td><td>22.20 ± 14.93</td><td>0.309</td></tr><tr align="left"><td>Tobacco exposure time (years)</td><td>31.08 ± 11.147</td><td>22.95 ± 11.422</td><td>0.058</td></tr><tr align="left"><td>Urinary cotinine (ng/mL)</td><td>1075 ± 979.72</td><td>1121.05 ± 738.37</td><td>0.881</td></tr><tr align="left"><td>FVC (%)</td><td>106.33 ± 10.47</td><td>112.75 ± 14.73</td><td>0.197</td></tr><tr align="left"><td>FEV1 (%)</td><td>97.17 ± 7.41</td><td>106.15 ± 13.176</td><td>0.039</td></tr><tr align="left"><td>FEV1/FVC (%)</td><td>76.08 ± 8.607</td><td>78.95 ± 4.774</td><td>0.306</td></tr><tr align="left"><td>FEF 25% (%)</td><td>94.25 ± 23.336</td><td>91.90 ± 20.843</td><td>0.770</td></tr><tr align="left"><td>FEF 50% (%)</td><td>88.92 ± 35.367</td><td>98.25 ± 29.963</td><td>0.431</td></tr><tr align="left"><td>FEF 75% (%)</td><td>57.17 ± 29.634</td><td>67.75 ± 24.253</td><td>0.280</td></tr><tr align="left"><td>FEF 25–75% (%)</td><td>77.67 ± 30.312</td><td>86.46 ± 23.676</td><td>0.368</td></tr><tr align="left"><td>PEF (%)</td><td>93 ± 20.657</td><td>90.45 ± 16.011</td><td>0.698</td></tr><tr align="left"><td>TLC (%)</td><td>101.47 ± 9.09</td><td>105.7 ± 15.448</td><td>0.391</td></tr><tr align="left"><td>RV (%)</td><td>100.67 ± 23.153</td><td>90.80 ± 29.163</td><td>0.327</td></tr><tr align="left"><td>RV/TLC (%)</td><td>31.92 ± 7.798</td><td>24.90 ± 6.357</td><td>0.009</td></tr><tr align="left"><td>Raw (L/s/cmH<span class="elsevierStyleInf">2</span>O)</td><td>0.205 ± 0.05</td><td>0.2674 ± 0.1028</td><td>0.061</td></tr><tr align="left"><td>sGaw (cmH<span class="elsevierStyleInf">2</span>O/L/s)</td><td>1.2867 ± 0.445</td><td>1.121 ± 0.565</td><td>0.393</td></tr><tr align="left"><td>Cardiothoracic index</td><td>0.45 ± 0.03</td><td>0.41 ± 0.04</td><td>0.056</td></tr></table><p class="elsevierStylePara">It was found that the mean age of the patients with tobacco-related pathologies was 48.33 years (SD = 10.13 years), which was higher than that of the group without pathologies (39.35 years, SD = 10.05 years), with statistically significant differences between the two groups (<span class="elsevierStyleItalic">p</span> < 0.05). The mean duration of exposure to tobacco was higher in the subgroup with tobacco-related pathologies (31.08 years, SD = 11.12), compared with the subgroup without pathologies (22.95 years, SD = 11.42), although without statistical significance.</p><p class="elsevierStylePara">With regard to the RV/TLC ratio, the cases with tobacco-related diseases had a higher mean (31.92%, SD = 7.80%) compared with the subgroup without pathologies (24.90%, SD = 6.36%, <span class="elsevierStyleItalic">p</span> < 0.05). The cases with the tobacco-related pathologies (12 cases) had higher tobacco consumption and lower cotinine compared with the subgroup without pathologies but without statistically significant differences (<span class="elsevierStyleItalic">p</span> > 0.05).</p><a name="sec0020" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Discussion</span><p class="elsevierStylePara">This study reflects a sample of asymptomatic smokers from the respiratory point of view, with high tobacco consumption. The age of onset of smoking was similar in both genders. The female subjects who presented to the HSM smoking cessation program were younger than the male subjects (mean age lower, <span class="elsevierStyleItalic">p</span> < 0.05). Tobacco consumption, mean duration of exposure to tobacco smoke, and urinary cotinine levels of the female subjects were below in comparison with of the male subjects (<span class="elsevierStyleItalic">p</span> < 0.05).</p><p class="elsevierStylePara">There were reduced FEV1/FVC, FEF 75%, FEF 25–75%, and cardiothoracic indices in cases and moderate inverse correlations between the TLC and cardiothoracic index, with statistical significance. The potential value of these variables was validated using the statistical significance found in the reduced sample. At the time of our study, 31.2% of the smokers showed extra-pulmonary pathologies related to tobacco consumption. Three smokers (9.38%) were diagnosed with subclinical COPD. Smokers with tobacco-related diseases had a higher mean age, a lower FEV1, and greater RV/TLC compared with smokers without pathologies (<span class="elsevierStyleItalic">p</span> < 0.05). These findings show individual susceptibility to the development of pulmonary disease in later life and/or show a decline of pulmonary function by age; this phenomenon was identified by Flecher. There was no statistical significance in terms of smoking history, mean duration of exposure to tobacco smoke, and urinary cotinine. This is determined by the homogeneity of the groups regarding tobacco consumption, because all the included smokers presented with high tobacco consumption.</p><p class="elsevierStylePara">As indicated in the previous studies, the FEV1 and FEV1/FVC ratio are not sensitive markers of early changes in lung pathophysiology or the emergence of COPD in smokers. Structural and functional changes are present in the smoker's lungs before the onset of clinical signs of airway obstruction. Thus, the underdiagnosis of early functional changes in chronic smoking represents an opportunity for early intervention.<a href="#bib10" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">, </span><a href="#bib14" class="elsevierStyleCrossRefs"><span class="elsevierStyleSup">7</span></a></p><p class="elsevierStylePara">Our sample reflects a population of smokers (young adults without underlying lung pathologies) with declining respiratory function parameters (reduction of mean values of FEV1/FVC, FEF 75% and FEF 25–75%) and lung hyperinflation compared with adult non-smokers in the same age group. In smokers with a history of tobacco-related extra-pulmonary disease, these changes may indicate pulmonary dysfunction at an early stage. We need to know which subgroup of individual susceptibility factors confer greater propensity for the harmful effects of tobacco; that is, which subgroup indicates that systemic disease with multiple organ involvement in COPD occurs as a late manifestation of the disease? The changes found in our study may reflect the premonitory signs of the progression to COPD at a later stage of disease in patients with extra-pulmonary pathologies related to tobacco.</p><p class="elsevierStylePara">In conclusion, smoking must be considered a disease which has potentially multisystemic repercussions. The study of the subgroup of patients with previous extrapulmonary pathologies related to tobacco has particular relevance for the demonstration of a greater individual susceptibility to the development of pulmonary alterations in a later spectrum of the illness. These findings show that a reduction of the mean values of FEV1/FVC, FEF 75%, FEF 25–75% and the cardiothoracic index may be indicative variables for the precocious detection of these patients.</p><p class="elsevierStylePara">This study has some limitations, in particular, the small sample size, the inclusion of a lower number of female smokers than male smokers, and the absence of evaluation of diffusing capacity for CO (DLCO).</p><p class="elsevierStylePara">With this preliminary study, we have sought to increase awareness of the variables that should be included in a prospective study; we intend to conduct future comparisons in the respiratory function variables and the cardiothoracic index of smokers before and after smoking cessation. These studies will aim to assess the possible reversibility of the changes found after smoking cessation.</p><a name="sec0025" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Ethical disclosures</span><a name="sec0030" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Protection of human and animal subjects</span><p class="elsevierStylePara">The authors declare that no experiments were performed on humans or animals for this study.</p><a name="sec0035" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Confidentiality of data</span><p class="elsevierStylePara">The authors declare that they have followed the protocols of their work center on the publication of patient data.</p><a name="sec0040" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Right to privacy and informed consent</span><p class="elsevierStylePara">The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.</p><a name="sec0045" class="elsevierStyleCrossRefs"></a><span class="elsevierStyleSectionTitle">Conflicts of interest</span><p class="elsevierStylePara">The authors have no conflicts of interest to declare.</p><p class="elsevierStylePara">Acknowledgments</p><p class="elsevierStylePara">The authors of this study would like to thank all of their colleagues and the technicians at the Sousa Martins Hospital, Local Health Unit, Guarda who participated in this study.</p><p class="elsevierStylePara">Received 15 March 2014 <br></br>Accepted 14 July 2014 </p><p class="elsevierStylePara">Corresponding author. ritad_gomes@hotmail.com</p>" "pdfFichero" => "320v21n03a90418839pdf001.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec640984" "palabras" => array:6 [ 0 => "Smoking" 1 => "Spirometry" 2 => "Plethysmography" 3 => "Cotinine" 4 => "Radiography" 5 => "Thoracic" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Objectives</span><br/><p class="elsevierStylePara">To investigate the respiratory function and lung hyperinflation in asymptomatic smokers without previous pulmonary pathology and with normal chest radiography. To identify tobacco-related diseases and to correlate tobacco consumption, duration of exposure to tobacco smoke and urinary cotinine with the existence of tobacco-related disease.</p><span class="elsevierStyleSectionTitle">Material and methods</span><br/><p class="elsevierStylePara">Case-controlled study with pairing by sex, age, and body mass index. Case definition: smokers who presented to the first appointment of smoking cessation at the Hospital Sousa Martins (HSM) without respiratory symptoms and with normal chest radiography. Definition of control: users without current and/or past tobacco exposition and with plethysmography and chest radiography at HSM within normal parameters.</p><span class="elsevierStyleSectionTitle">Results</span><br/><p class="elsevierStylePara">Reductions in FEV1/FVC, FEF 75%, FEF 25–75% and the cardiothoracic index were detected in smokers and showed a moderated inverse correlation of TLC (with statistical meaning) compared with the control group. Approximately 31.2% of the smokers showed extrapulmonary disease related to tobacco, and 9.38% of the smokers exhibited subclinical chronic obstructive pulmonary disease (COPD). Smokers with tobacco-related diseases presented a mean age and RV/TLC ratio superior to smokers without pathology.</p><span class="elsevierStyleSectionTitle">Discussion</span><br/><p class="elsevierStylePara">The reduction of the mean values of FEV1/FVC, FEF 75%, FEF 25–75% and the cardiothoracic index seems to indicate precocious pulmonary dysfunction. This work aims to reveal the importance of detecting premonitory anomalies of pulmonary disease during the subclinical phase in patients at risk. Smoking must be considered a factor of multisystemic repercussion; thus, intervention opportunities in this particular group must not be wasted. This preliminary study identifies potentially promising variables with the aim of testing the hypothesis that there can be premonitory alterations in COPD, according to its evolution versus reversibility after smoking cessation. This work will be concluded in a future study.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib8" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Health effects of cigarette smoking. Clin Chest Med. 1991; 12:643-58. [Epub 01.12.91]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Health effects of cigarette smoking." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Sherman CB." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Chest Med. " "fecha" => "1991" "volumen" => "12" "paginaInicial" => "643" "paginaFinal" => "658" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1747984" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib9" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Global Initiative for Chronic Obstructive Lung Disease (GOLD)." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Global Strategy for the Diagnosis MaPoC." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "titulo" => "Global Initiative for Chronic Obstructive Lung Disease (GOLD)." "fecha" => "2014" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib10" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lung dysfunction of chronic smokers with no signs of COPD. COPD. 2011; 8:189-95. [Epub 26.04.11]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Lung dysfunction of chronic smokers with no signs of COPD." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Nagelmann A" 1 => "Tonnov A" 2 => "Laks T" 3 => "Sepper R" 4 => "Prikk K." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/15412555.2011.565090" "Revista" => array:6 [ "tituloSerie" => "COPD. " "fecha" => "2011" "volumen" => "8" "paginaInicial" => "189" "paginaFinal" => "195" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21513442" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib11" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med. 2009; 15:303-7. [Epub 07.05.09]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Lee G" 1 => "Walser TC" 2 => "Dubinett SM." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MCP.0b013e32832c975a" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pulm Med. " "fecha" => "2009" "volumen" => "15" "paginaInicial" => "303" "paginaFinal" => "307" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19417670" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib12" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 2007; 87:1047-82. [Epub 07.07.07]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Yoshida T" 1 => "Tuder RM." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1152/physrev.00048.2006" "Revista" => array:6 [ "tituloSerie" => "Physiol Rev. " "fecha" => "2007" "volumen" => "87" "paginaInicial" => "1047" "paginaFinal" => "1082" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17615396" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib13" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007; 30:616-22. [Epub 02.10.07]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Young RP" 1 => "Hopkins R" 2 => "Eaton TE." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00021707" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J. " "fecha" => "2007" "volumen" => "30" "paginaInicial" => "616" "paginaFinal" => "622" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17906084" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib14" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Underdiagnosis of chronic obstructive pulmonary disease: a rationale for spirometry as a screening tool. J Can Thorac Soc. 2001; 8:153-8. [Epub 23.06.01]" "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "Underdiagnosis of chronic obstructive pulmonary disease: a rationale for spirometry as a screening tool." "idioma" => "en" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "McIvor RA" 1 => "Tashkin DP." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Can Thorac Soc. " "fecha" => "2001" "volumen" => "8" "paginaInicial" => "153" "paginaFinal" => "158" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08732159/0000002100000003/v0_201604141146/X0873215915188393/v0_201604141146/en/main.assets" "Apartado" => array:4 [ "identificador" => "18133" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Artigos originais" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/08732159/0000002100000003/v0_201604141146/X0873215915188393/v0_201604141146/en/320v21n03a90418839pdf001.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0873215915188393?idApp=UINPBA00004E" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 10 | 6 | 16 |
| 2024 October | 56 | 46 | 102 |
| 2024 September | 78 | 29 | 107 |
| 2024 August | 94 | 58 | 152 |
| 2024 July | 83 | 40 | 123 |
| 2024 June | 84 | 32 | 116 |
| 2024 May | 48 | 29 | 77 |
| 2024 April | 65 | 31 | 96 |
| 2024 March | 55 | 32 | 87 |
| 2024 February | 67 | 26 | 93 |
| 2024 January | 59 | 29 | 88 |
| 2023 December | 44 | 29 | 73 |
| 2023 November | 59 | 44 | 103 |
| 2023 October | 58 | 37 | 95 |
| 2023 September | 44 | 31 | 75 |
| 2023 August | 57 | 19 | 76 |
| 2023 July | 66 | 30 | 96 |
| 2023 June | 79 | 22 | 101 |
| 2023 May | 73 | 31 | 104 |
| 2023 April | 68 | 22 | 90 |
| 2023 March | 110 | 14 | 124 |
| 2023 February | 82 | 27 | 109 |
| 2023 January | 48 | 18 | 66 |
| 2022 December | 60 | 36 | 96 |
| 2022 November | 95 | 41 | 136 |
| 2022 October | 74 | 29 | 103 |
| 2022 September | 50 | 43 | 93 |
| 2022 August | 59 | 31 | 90 |
| 2022 July | 62 | 49 | 111 |
| 2022 June | 51 | 34 | 85 |
| 2022 May | 79 | 38 | 117 |
| 2022 April | 60 | 34 | 94 |
| 2022 March | 34 | 47 | 81 |
| 2022 February | 36 | 43 | 79 |
| 2022 January | 43 | 37 | 80 |
| 2021 December | 27 | 37 | 64 |
| 2021 November | 30 | 40 | 70 |
| 2021 October | 41 | 50 | 91 |
| 2021 September | 26 | 25 | 51 |
| 2021 August | 26 | 18 | 44 |
| 2021 July | 27 | 17 | 44 |
| 2021 June | 35 | 24 | 59 |
| 2021 May | 67 | 26 | 93 |
| 2021 April | 123 | 73 | 196 |
| 2021 March | 92 | 20 | 112 |
| 2021 February | 80 | 19 | 99 |
| 2021 January | 39 | 12 | 51 |
| 2020 December | 42 | 5 | 47 |
| 2020 November | 51 | 16 | 67 |
| 2020 October | 38 | 17 | 55 |
| 2020 September | 52 | 28 | 80 |
| 2020 August | 67 | 22 | 89 |
| 2020 July | 80 | 21 | 101 |
| 2020 June | 84 | 18 | 102 |
| 2020 May | 78 | 15 | 93 |
| 2020 April | 79 | 8 | 87 |
| 2020 March | 71 | 8 | 79 |
| 2020 February | 68 | 21 | 89 |
| 2020 January | 89 | 14 | 103 |
| 2019 December | 57 | 16 | 73 |
| 2019 November | 89 | 17 | 106 |
| 2019 October | 70 | 15 | 85 |
| 2019 September | 77 | 28 | 105 |
| 2019 August | 111 | 10 | 121 |
| 2019 July | 92 | 9 | 101 |
| 2019 June | 107 | 12 | 119 |
| 2019 May | 116 | 34 | 150 |
| 2019 April | 115 | 27 | 142 |
| 2019 March | 100 | 12 | 112 |
| 2019 February | 114 | 6 | 120 |
| 2019 January | 114 | 27 | 141 |
| 2018 December | 51 | 9 | 60 |
| 2018 November | 24 | 0 | 24 |
| 2018 October | 28 | 11 | 39 |
| 2018 September | 28 | 11 | 39 |
| 2018 August | 33 | 27 | 60 |
| 2018 July | 23 | 21 | 44 |
| 2018 June | 30 | 18 | 48 |
| 2018 May | 33 | 19 | 52 |
| 2018 April | 35 | 17 | 52 |
| 2018 March | 56 | 18 | 74 |
| 2018 February | 18 | 16 | 34 |
| 2018 January | 17 | 22 | 39 |
| 2017 December | 27 | 23 | 50 |
| 2017 November | 15 | 24 | 39 |
| 2017 October | 13 | 6 | 19 |
| 2017 September | 10 | 15 | 25 |
| 2017 August | 14 | 18 | 32 |
| 2017 July | 16 | 11 | 27 |
| 2017 June | 26 | 24 | 50 |
| 2017 May | 28 | 19 | 47 |
| 2017 April | 10 | 7 | 17 |
| 2017 March | 10 | 13 | 23 |
| 2017 February | 5 | 5 | 10 |
| 2017 January | 9 | 8 | 17 |
| 2016 December | 17 | 9 | 26 |
| 2016 November | 9 | 2 | 11 |
| 2016 October | 2 | 4 | 6 |
| 2016 September | 5 | 2 | 7 |
| 2016 August | 5 | 4 | 9 |
| 2016 July | 4 | 9 | 13 |
| 2016 June | 15 | 0 | 15 |
| 2016 May | 0 | 7 | 7 |
| 2016 April | 23 | 4 | 27 |
| 2016 March | 26 | 6 | 32 |
| 2016 February | 37 | 13 | 50 |
| 2016 January | 32 | 15 | 47 |
| 2015 December | 25 | 12 | 37 |
| 2015 November | 18 | 8 | 26 |
| 2015 October | 22 | 18 | 40 |
| 2015 September | 53 | 30 | 83 |
| 2015 August | 49 | 38 | 87 |
| 2015 July | 41 | 30 | 71 |
| 2015 June | 63 | 43 | 106 |
| 2015 May | 187 | 121 | 308 |
Show all
